Hello Everyone,
The markets are SOARING! The S&P is printing new all-time-highs and small caps are paying investors and traders alike. With all the talk about Brexit, jobs numbers and gold, you’d think that most sectors on Wall Street are in a coma. But not biotech!
If you’ve followed my alerts long enough you’ll know how much I believe in this ‘evergreen’ corner of Wall Street. It’s outperformed almost every sector in the last 15 years so it shouldn’t surprise you that I have unearthed a very sweet near term trade opportunity.
The company is coming off a fresh acquisition that gives it access to the $65B antibiotic market. In addition to this new-found potential profit center the company already has an advanced stage product that treats hemorrhoids.
Take your eyes and ears away from all the ‘noisy’ distractions and focus on this gem I have found for you...
Our Brand New Biotech Bull Report is:
Citius Pharmaceuticals, Inc.: CTXR
CTXR is poised for Strong Long Term Growth;
1. Access to the $65B a year antibiotic market - Biotech industry has always been and will always be at the forefront of emerging bull markets in all investors and traders eyes for great reason!
2. An established stage 2b product in the hemorrhoids treatment market in which more than 600K+ people in the developed world. Even if just scratching and tapping the surface of this condition, it's safe to say gaining a small fraction of market share would potentially catapult the price tag of CTXR to all-new-heights not to mention assist in helping many folks in the process.
A Look Inside: Citius Pharmaceuticals, Inc.
CTXR (Citius Pharmaceuticals, Inc.) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. By using previously approved drugs with substantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development.
Citius is currently advancing two proprietary product candidates, our Mino-Lok™ product and a Hydrocortisone-Lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care.
CTXR was founded in 2007 and is based in Maynard, Massachusetts. Start your research here at the company's website: http://www.citiuspharma.com/
The Press Wire: CTXR Citius Pharmaceuticals
Discontinues Suprenza(TM) to Focus on Core Assets!
CTXR announced recently, that it was discontinuing Suprenza, its FDA-approved phentermine-based product for weight loss.
Myron Holubiak, CEO of Citius said, "Suprenza no longer meets our core strategic objectives. We are dedicating our focus on our Phase 3 asset Mino-Lok and our Phase 2b asset Hydro-Lido for hemorrhoids." Holubiak continued, "We feel that the obesity and weight management market has shifted and therefore we are devoting our efforts on developing our leading two assets. We anticipate a minimal financial impact to Citius from discontinuation since we eliminate our ongoing regulatory expenses and have not historically received royalties from the product."
Read the full news source here: http://www.barchart.com/headlines/story/116076/citius-pharmaceuticals-discontinues-suprenza-tm-to-focus-on-core-assets
CTXR: This Biotech Bull is Experiencing a Rally In-Progress!
CTXR - This chart warrants your immediate attention: http://www.barchart.com/interactive_charts/stocks/CTXR
CTXR is trading below its 50 DMA of 1.31 which means a possible 43% upside opportunity in the near term.
RSI is currently 45 on the daily chart which suggests not just bounce potential, but also that traders can enjoy multiple entry/exits before the stock reaches overbought territories.
CTXR has added +31% to its 52-week low of 0.70 since early July 2016.
It would be difficult to find a more compelling technical setup then CTXR here; the stock is a text-book alert that is just warming up with strong awareness yet to come! It's been gaining momentum the last several sessions not to mention currently trading at extremely low-priced valuations!
Bottomline here is this represents a pure play on the one of the most sought-after growing industries in the world bar-none! Act and react accordingly now...
Before turning on the BBQ this evening, take a quick 30 seconds towards executing best possible entries and fills immediately by keyword logging our SMS text message system and get our profiled ticker at the soonest possible moment.
Yes, simple as texting the word, "StockRun" to 25827 right now and you're done!
info@StockRunway.com
Copyright© 2010 StockRunway.com All Rights Reserved. Protected by copyright laws of the United States and international treaties. This email may only be used pursuant to the subscription agreement controlling use of the StockRunway financial web site and any reproduction, copying, or redistribution of this email or its contents, in whole or in part, is strictly prohibited without the express written permission of StockRunway.com.
LEGAL DISCLAIMER: Neither StockRunway nor any of its employees are registered investment advisors or a Broker/Dealer. As such, StockRunway does not offer or provide personalized investment insight. Although StockRunway may answer general customer service questions, they are not licensed under securities laws to address your particular investment situation. Nothing in this report, nor any communication by our employees to you should be considered personalized investment insight.
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. StockRunway.com is often times compensated to feature certain companies. These third party, may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.
Release of Liability: Through use of this website viewing or using you agree to hold StockRunway.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. StockRunway.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. StockRunway.com is owned and operated by MantleMediaLLC. MantleMediaLLC has been compensated two thousand dollars for the marketing awareness effort on CTXR towards this two day featured advertisement by a third party shareholder ThirdCoastMedia. MantleMediaLLC has not investigated the background of the hiring third party/company. Anyone viewing this newsletter should assume the hiring party or affiliates of the hiring party own shares which they may plan to liquidate, further understanding that the liquidation of those shares may negatively impact the share price. Any compensation received by MantleMedia LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. MantleMedia LLC nor StockRunway has not purchased and does not have any shares of CTXR. Any compensation received by MantleMediaLLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. MantleMediaLLC has not investigated the background of the third party shareholder. All information on featured companies is provided by the companies profiled, or is available from public sources and StockRunway.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. MantleMediaLLC nor Stockrunway.com does not own and has not purchased any shares of the above company.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead StockRunway.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. StockRunway.com is compliant with the Can Spam Act of 2003. StockRunway.com does not offer such advice or analysis, StockRunway.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.These are paid advertisements used to generate exposure and awareness about the company or companies mentioned in our newsletters.
For full disclaimer please visit our website: http://www.StockRunway.com/disclaimer
|
« Our Ace Pilot lives by one simple measure of success...Yours! »
|
|
